RZLT · Rezolute

The thesis

Rezolute's value still rests on the upLIFT study of ersodetug in tumor hyperinsulinism (low blood sugar caused by excess insulin from tumors), with topline guided to mid-December 2026. The final responder rate against the 7-of-8 interim settles the case, and a new $400 million mixed-securities registration filed 5 November 2026 adds the chance of a financing before the result.

The shares closed at $4.02 on 10 November 2026, 63.3% below the 52-week high of $10.94 and down 12.6% over three months (split- and dividend-adjusted daily closes). The 14-period relative strength index (RSI) was 58.7. The close was $4.22 on 28 October 2026, $3.90 on 15 October 2026 and $3.84 on 18 September 2026.

The story is well known: the topline date is set, and the only new items since the 14 October 2026 enrollment release are the 5 November 2026 first-quarter report and the registration statement. The sunRIZE trial in congenital hyperinsulinism missed its primary endpoint (company topline, 11 December 2025), so the tumor study carries the pipeline.

Bullish and bearish views on Rezolute, Inc.

The bull case on Rezolute, Inc. (RZLT), in brief: the topline has a date. The bear case: a registration statement is on file.

Bull case

• The topline has a date. Rezolute's 5 November 2026 first-quarter release repeats that enrollment is complete and topline is expected by mid-December 2026 (BiopharmaWatch summary of the release).
• The interim was strong. Seven of the first eight upLIFT participants met the primary endpoint, up from six on 2 June 2026. The eighth participant discontinued the drug shortly after enrollment and later died of cancer progression; Rezolute counts that participant as a non-responder. The release reports no drug-related safety findings.
• A filing path exists in 2027. Rezolute plans to submit a biologics license application (BLA) for ersodetug for one or potentially both indications in 2027. The FDA recommended filing for congenital disease after the pre-BLA process, though Rezolute says there is no assurance the agency will agree the evidence supports approval (release of 5 November 2026).
• Analyst targets sit far above the price. Cantor Fitzgerald upgraded the shares to Overweight on 6 October 2026, Citizens raised its target to $15 and Lake Street raised its target to $12 (Benzinga). Maxim's target is $14 (3 June 2026), Guggenheim's is $11 (15 June 2026) and HC Wainwright's is $10 (25 September 2026).
• Spending is flat to lower. Fiscal first-quarter research and development expense was $12.8 million against $13.1 million a year earlier, and general and administrative expense was $6.6 million against $6.7 million (BiopharmaWatch summary of the 5 November 2026 release).

Bear case

• A registration statement is on file. Rezolute filed a prospectus for a $400 million mixed-securities registration on 5 November 2026 (company news; SEC Form S-3 fee exhibit lists a $400,000,000 universal registration). Prior financings used common stock plus pre-funded warrants, so a sale before topline would dilute holders. No offering or sales agreement under it has been reported.
• Cash is falling. Cash and marketable securities were $90.0 million at 30 September 2026 against $107.8 million at 30 June 2026, and the quarterly net loss was $18.5 million (BiopharmaWatch summary of the 5 November 2026 release). Cash was $167.9 million a year before the June 2026 figure.
• Eight more participants can dilute the rate. The interim covers half of the study. A final responder share well below 7 of 8 would remove the second indication after the sunRIZE miss. Eight participants is too small a sample to support a conclusion about the final rate.
• The shares have not rewarded the news. The close was $4.02 on 10 November 2026 against $4.01 on 2 October 2026, before the FDA recommendation, the upgrade and the target increases. The three-month change is negative 12.6%.
• The congenital path is unproven. The FDA said any view on approvability would come only in a formal BLA review (company release, 5 October 2026).

Price setup

The shares closed at $4.02 on 10 November 2026. That is above the 18 September 2026 close of $3.84 and the 15 October 2026 close of $3.90, and well below the 52-week high of $10.94. The RSI of 58.7 is up from 40.6 on 28 October 2026 and from 24.0 on 18 September 2026, although the close is 4.7% lower than on 28 October 2026.

Crowding evidence is limited to what can be observed: the topline is about five weeks away, and a $400 million registration is on file with no reported use. The shares sit far below every analyst target cited above, and no heavy retail attention is visible in company news. SEC Form 4 insider transactions were not reviewed for this refresh.

The range of closes since mid-September ($3.84 to $4.22 on the dates cited) is narrow compared with the distance to the 52-week high. A move through either end is more likely to come from the topline than from the quarterly report.

Catalysts ahead

• ~15 December 2026 (est.): upLIFT full topline in tumor hyperinsulinism (company guidance of mid-December 2026, reaffirmed 5 November 2026). The binary event: a responder rate near 7 of 8 moves the asset toward a 2027 filing, while a diluted rate removes the second indication.

Elapsed catalysts

• 12 November 2026 (est.): Any prospectus supplement or pricing release under the $400 million registration filed 5 November 2026; no date is set. An offering before topline would dilute holders; its absence leaves the readout funded by $90.0 million of cash. (passed)

What would change the view

A daily close below $3.70, under the 18 September 2026 close of $3.84 and the 15 October 2026 close of $3.90. A final upLIFT responder rate well below the 7-of-8 interim, or an equity offering priced before topline, would also break the case.

The risks this note tracks, each with what would confirm it:

• An equity offering is priced before the readout, converting a funded binary into a diluted one. Confirmed by: a prospectus supplement, offering release or sales agreement filed under the $400 million registration of 5 November 2026.
• The eight newly enrolled participants dilute the responder rate below the 7-of-8 interim. Confirmed by: a final responder proportion at topline materially under the interim rate.
• Topline slips past mid-December. Confirmed by: company language moving from 'mid-December' to 2027 or to a later month.
• The congenital program cannot support a filing despite the FDA's recommendation. Confirmed by: FDA feedback or BLA-review language that the sunRIZE data do not support approval.

What it trades with

Rezolute trades on its own clinical calendar. No current theme carries the name, and moves around the 2 June 2026 interim came from company data rather than sector flow. Single-asset, small-cap biotechs with near-term readouts tend to move with the small-cap biotech group on risk appetite and with their own financing news. This note does not measure that relationship for Rezolute.